Business
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
BOSTON, March 04, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three months and full year ended December 31, 2025, and highlighted recent progress.
About this update from Verastem, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/3007a74d18f86ca198884e2607d18e56"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3xWRlgpmBA8hRzG0NzQjvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3007a74d18f86ca198884e2607d18e56","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4iJQsZF6E2T9E7sQZ4vBtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/3007a74d18f86ca198884e2607d18e56","width":1024,"height":512}},"lazy":false},{"type":"text","content":"AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025","length":189,"tagName":"p","attribs":{}},{"type":"text","content":"Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab","length":252,"tagName":"p","attribs":{}},{"type":"text","content":"Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs; continuing higher dose evaluations","length":214,"tagName":"p","attribs":{}},{"type":"text","content":"Company cash, cash equivalents, and investments of $205 million as of December 31, 2025; pro-forma year-end cash, cash equivalents and investments of $234 million inclusive of net proceeds from exercise of expiring cash warrants; expected cash runway into first half of 2027","length":274,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, March 04, 2026--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three months and full year ended December 31, 2025, and highlighted recent progress.","length":316,"tagName":"p"},{"type":"text","content":""2025 was a transformative year for us, high...